[HTML][HTML] The global impact of COVID-19 on solid organ transplantation: two years into a pandemic

A Nimmo, D Gardiner, I Ushiro-Lumb, R Ravanan… - …, 2022 - journals.lww.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has had a major global
impact on solid organ transplantation (SOT). An estimated 16% global reduction in …

Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the …

L Nab, EPK Parker, CD Andrews, WJ Hulme… - The Lancet public …, 2023 - thelancet.com
Background COVID-19 has been shown to differently affect various demographic and
clinical population subgroups. We aimed to describe trends in absolute and relative COVID …

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal …

MYM Yusof, J Arnold, B Saleem… - The Lancet …, 2023 - thelancet.com
Background Concerns have been raised regarding the reduced immunogenicity of vaccines
against COVID-19 in patients with autoimmune diseases treated with rituximab. However …

Incidence and risk factors of COVID-19 vaccine breakthrough infections: a prospective cohort study in Belgium

V Stouten, P Hubin, F Haarhuis, JAF van Loenhout… - Viruses, 2022 - mdpi.com
The objective of this study was to investigate the incidence and risk factors associated with
COVID-19 vaccine breakthrough infections. We included all persons≥ 18 years that had …

[HTML][HTML] Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities

PD Smits, S Gratzl, M Simonov, SK Nachimuthu… - Vaccine, 2023 - Elsevier
Background The successful development of multiple COVID-19 vaccines has led to a global
vaccination effort to reduce severe COVID-19 infection and mortality. However, the …

SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review

X Jing, M Han, X Wang, L Zhou - BMC infectious diseases, 2023 - Springer
Abstract Background Corona Virus Disease 2019 (COVID-19) mRNA vaccine effectiveness
(VE) has recently declined, and reports about COVID-19 breakthrough infection have …

[HTML][HTML] Comparison of vaccine effectiveness against the omicron (B. 1.1. 529) variant in hemodialysis patients

KJ Spensley, S Gleeson, P Martin, T Thomson… - Kidney international …, 2022 - Elsevier
Results A total of 1121 in-center hemodialysis patients were included in the analysis; all
patients underwent weekly screening for SARS-CoV-2 infection via reverse transcriptase …

Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease …

P Martin, S Gleeson, CL Clarke, T Thomson… - The Lancet Regional …, 2022 - thelancet.com
Background People with end-stage kidney disease, including people on haemodialysis, are
susceptible to greater COVID-19 related morbidity and mortality. This study compares the …

Outpatient treatment with AZD7442 (tixagevimab/cilgavimab) prevented COVID-19 hospitalizations over 6 months and reduced symptom progression in the TACKLE …

FDR Hobbs, H Montgomery, F Padilla… - Infectious Diseases and …, 2023 - Springer
Introduction We assessed effects of AZD7442 (tixagevimab/cilgavimab) on deaths from any
cause or hospitalizations due to coronavirus disease 2019 (COVID-19) and symptom …

Humoral and cellular responses to SARS‐CoV‐2 in patients with B‐cell haematological malignancies improve with successive vaccination

CL Pinder, D Jankovic, TA Fox… - British Journal of …, 2023 - Wiley Online Library
Patients with haematological malignancies are more likely to have poor responses to
vaccination. Here we provide detailed analysis of the humoral and cellular responses to …